1. Home
  2. RCKT vs PRG Comparison

RCKT vs PRG Comparison

Compare RCKT & PRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RCKT
  • PRG
  • Stock Information
  • Founded
  • RCKT 1999
  • PRG 2020
  • Country
  • RCKT United States
  • PRG United States
  • Employees
  • RCKT N/A
  • PRG N/A
  • Industry
  • RCKT Biotechnology: Pharmaceutical Preparations
  • PRG Diversified Commercial Services
  • Sector
  • RCKT Health Care
  • PRG Consumer Discretionary
  • Exchange
  • RCKT Nasdaq
  • PRG Nasdaq
  • Market Cap
  • RCKT 264.0M
  • PRG 1.1B
  • IPO Year
  • RCKT N/A
  • PRG N/A
  • Fundamental
  • Price
  • RCKT $2.99
  • PRG $30.18
  • Analyst Decision
  • RCKT Buy
  • PRG Strong Buy
  • Analyst Count
  • RCKT 13
  • PRG 5
  • Target Price
  • RCKT $18.50
  • PRG $41.80
  • AVG Volume (30 Days)
  • RCKT 3.8M
  • PRG 385.5K
  • Earning Date
  • RCKT 08-04-2025
  • PRG 07-23-2025
  • Dividend Yield
  • RCKT N/A
  • PRG 1.70%
  • EPS Growth
  • RCKT N/A
  • PRG 99.08
  • EPS
  • RCKT N/A
  • PRG 4.90
  • Revenue
  • RCKT N/A
  • PRG $2,505,714,000.00
  • Revenue This Year
  • RCKT N/A
  • PRG $1.36
  • Revenue Next Year
  • RCKT N/A
  • PRG $4.29
  • P/E Ratio
  • RCKT N/A
  • PRG $6.11
  • Revenue Growth
  • RCKT N/A
  • PRG 4.62
  • 52 Week Low
  • RCKT $2.19
  • PRG $23.50
  • 52 Week High
  • RCKT $26.98
  • PRG $50.28
  • Technical
  • Relative Strength Index (RSI)
  • RCKT 45.55
  • PRG 56.16
  • Support Level
  • RCKT $2.76
  • PRG $29.85
  • Resistance Level
  • RCKT $3.24
  • PRG $30.83
  • Average True Range (ATR)
  • RCKT 0.19
  • PRG 0.79
  • MACD
  • RCKT 0.17
  • PRG 0.06
  • Stochastic Oscillator
  • RCKT 74.85
  • PRG 75.82

About RCKT Rocket Pharmaceuticals Inc.

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.

About PRG PROG Holdings Inc.

PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The company has two reportable segments: Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the Progressive Leasing segment.

Share on Social Networks: